Last reviewed · How we verify
NCT03541551
Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy
NA trial testing CTT with ologen® Collagen Matrix in Primary Congenital Glaucoma in 44 participants. Completed in 1 September 2019.
1 September 2019
Quick facts
| Lead sponsor | L.V. Prasad Eye Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 13 July 2018 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 September 2019 |
| Sites | 1 location across India |
Drugs / interventions tested
- CTT with ologen® Collagen Matrix
- Trab Trab
Conditions studied
- Primary Congenital Glaucoma — all drugs for Primary Congenital Glaucoma →
- Developmental Glaucoma — all drugs for Developmental Glaucoma →
- Infantile Glaucoma — all drugs for Infantile Glaucoma →
Sponsor
L.V. Prasad Eye Institute
Who can join
Adults 1 Month to 3, any sex, with Primary Congenital Glaucoma or Developmental Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To the best of Investigator knowledge, no studies to this date have compared the safety and efficacy of ologen® Collagen Matrix in Primary congenital glaucoma (PCG) patients undergoing trabeculectomy. Given that filtration surgery is usually less successful in patients with developmental glaucoma; the purpose of this study is to compare combined trabeculectomy with trabeculotomy (CTT) with adjuvant ologen® Collagen Matrix versus CTT without ologen® in children with PCG. Investigator hypothesis is that CTT with ologen® Collagen Matrix would be as effective as CTT in IOP control, but with reduced scarring and long term healthier bleb morphology.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Surgical interventions for primary congenital glaucoma.
Gagrani M, Garg I, Ghate D. · · 2020 · cited 14× · PMID 32816311 · DOI 10.1002/14651858.cd008213.pub3 -
Device-modified trabeculectomy for glaucoma.
Park J, Rittiphairoj T, Wang X, E JY, et al · · 2023 · cited 6× · PMID 36912740 · DOI 10.1002/14651858.cd010472.pub3
Verify or expand the search:
- PubMed search for NCT03541551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other L.V. Prasad Eye Institute trials
Trials by the same sponsor.
- NCT04843839 — CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops · Phase 2 · unknown
- NCT04618510 — SEED-LVPEI Myopia Study · NA · unknown
- NCT06613919 — Six-months Versus Nine-months ATT for Ocular TB · Phase 4 · completed
- NCT03548805 — Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma · NA · completed
- NCT03230058 — Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03541551 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by L.V. Prasad Eye Institute
- Last refreshed: 12 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03541551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing